<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157686</url>
  </required_header>
  <id_info>
    <org_study_id>MT10109L-004</org_study_id>
    <secondary_id>2014-005303-24</secondary_id>
    <nct_id>NCT04157686</nct_id>
  </id_info>
  <brief_title>MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)</brief_title>
  <official_title>A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in&#xD;
      participants with moderate to severe GL and/or LCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">January 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experienced an adverse event</measure>
    <time_frame>Baseline to Day 720</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in pulse rate (beats per minute)</measure>
    <time_frame>Baseline to Day 720</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in blood pressure (mm Hg)</measure>
    <time_frame>Baseline to Day 720</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in respiratory rate (breaths per minute)</measure>
    <time_frame>Baseline to Day 720</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with binding and neutralizing antibodies</measure>
    <time_frame>Baseline to Day 720</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Glabellar Lines</condition>
  <condition>Lateral Canthal Lines</condition>
  <arm_group>
    <arm_group_label>MT10109L Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT10109L Dose 1 will be injected into the GL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT10109L Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT10109L Dose 2 will be injected into the LCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT10109L Dose 1 + Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 will be injected into the LCL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT10109L</intervention_name>
    <description>MT10109L will be injected into either the GL, LCL, or both the LCL and GL.</description>
    <arm_group_label>MT10109L Dose 1</arm_group_label>
    <arm_group_label>MT10109L Dose 1 + Dose 2</arm_group_label>
    <arm_group_label>MT10109L Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completion of lead-in Phase 3 study;&#xD;
&#xD;
          -  Female participants must not be pregnant or planning to get pregnant and willing to&#xD;
             minimize the risk of inducing pregnancy for the duration of the clinical study and&#xD;
             follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known immunization or hypersensitivity to any botulinum toxin serotype;&#xD;
&#xD;
          -  Any medical condition that may put the participant at increased risk with exposure to&#xD;
             MT10109L including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic&#xD;
             lateral sclerosis, or any other condition that might interfere with neuromuscular&#xD;
             function;&#xD;
&#xD;
          -  Known allergy or sensitivity to any of the components of the study interventions, or&#xD;
             any materials used in the study procedures;&#xD;
&#xD;
          -  Females who are pregnant, nursing, or planning a pregnancy during the study;&#xD;
&#xD;
          -  Participants who plan for an extended absence away from the immediate area of the&#xD;
             study site that would preclude them from returning for all protocol-specified study&#xD;
             visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmington Dermatology Center /ID# 233019</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc. /ID# 232727</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

